Context Therapeutics’ (CNTX) “Buy” Rating Reiterated at Guggenheim

Guggenheim reaffirmed their buy rating on shares of Context Therapeutics (NASDAQ:CNTX) in a research note released on Tuesday morning,Benzinga reports. They currently have a $5.00 target price on the stock.

Other research analysts have also issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, January 21st. JonesTrading began coverage on Context Therapeutics in a research note on Monday, December 22nd. They set a “buy” rating and a $7.00 target price for the company. Piper Sandler lifted their target price on Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a report on Tuesday. Lifesci Capital raised Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. Finally, Wall Street Zen upgraded Context Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $6.60.

Context Therapeutics Stock Down 4.9%

CNTX opened at $2.54 on Tuesday. Context Therapeutics has a twelve month low of $0.49 and a twelve month high of $3.62. The company has a fifty day moving average of $2.46 and a 200-day moving average of $1.61. The stock has a market cap of $233.38 million, a PE ratio of -6.68 and a beta of 1.96.

Context Therapeutics (NASDAQ:CNTX) last released its earnings results on Monday, March 23rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Sell-side analysts anticipate that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Trading of Context Therapeutics

Several hedge funds have recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in Context Therapeutics during the 4th quarter valued at $43,000. Quadrature Capital Ltd bought a new position in shares of Context Therapeutics in the fourth quarter valued at $68,000. Clear Harbor Asset Management LLC grew its holdings in shares of Context Therapeutics by 60.5% during the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after buying an additional 35,000 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Context Therapeutics during the third quarter valued at about $100,000. Finally, XTX Topco Ltd increased its position in shares of Context Therapeutics by 858.8% during the fourth quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock worth $149,000 after acquiring an additional 91,008 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics News Roundup

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target for CNTX to $7.00, giving investors a higher valuation anchor that could support upside if clinical or commercial progress validates the view. Piper Sandler Raises Context Therapeutics (NASDAQ:CNTX) Price Target to $7.00
• Positive Sentiment: Guggenheim initiated (or reiterated) a Buy on CNTX, a bullish signal that can attract momentum buyers and institutional interest. Context Therapeutics (NASDAQ:CNTX) Earns Buy Rating from Guggenheim
• Positive Sentiment: D. Boral Capital also gave CNTX a Buy rating, adding to the cluster of bullish broker opinions that may support demand at current levels. Context Therapeutics (NASDAQ:CNTX) Earns “Buy” Rating from D. Boral Capital
• Neutral Sentiment: HC Wainwright’s report includes a long‑range projection of a modestly positive FY2030 EPS ($0.08), implying the firm expects potential profitability by the end of the decade — a distant, high‑uncertainty view. MarketBeat: Context Therapeutics analyst note summary
• Negative Sentiment: HC Wainwright (analyst E. Bodnar) cut multiple near‑term EPS estimates on March 24th — trimming Q1–Q4 2026 and lowering FY2026–FY2029 forecasts (FY2026 revised to -$0.60 from -$0.49; FY2027–FY2029 also materially lowered). Those downgrades signal weaker expected near‑term economics and drove downward pressure on the stock today. MarketBeat: HC Wainwright cuts Context Therapeutics EPS estimates

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.